ClinicalTrials.gg
RecruitingNCT07503886Updated Oct 22, 2026

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

A Phase 2 interventional study of DFL24498 and Vehicle in Dry Eye Disease (DED), sponsored by Dompé Farmaceutici S.p.A. Recruiting at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Dompé Farmaceutici S.p.A.

Started
2026
the only one that year
Phase 2
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, this one is the only one that started in 2026, is one of 5 in phase 2, and was the 10th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease. Approximately 417 participants aged 18 years or older who meet all eligibility criteria will be enrolled at study sites in the US. The study duration will be up to 16 weeks and will consist of three periods.

03

Conditions studied

  • Dry Eye Disease (DED)

Keywords

  • Dry Eye Disease
  • DFL24498
  • Ocular discomfort
  • Eye dryness
  • Topical ophthalmic solution
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A diagnosis of DED at least 6 months before enrollment (current use or recommended use of artificial tears for the treatment of dry eye).
  • The global score of the SANDE questionnaire ≥ 30
  • DED in at least one eye which is characterized by the following clinical features:

    1. Schirmer I test without anesthesia \< 10 mm/5 minutes, and
    2. Total CFS grade ≥ 4 assessed by the NEI grading system, and
    3. Fluorescein tear film break-up time (TFBUT) \< 10 seconds.
  • Best corrected visual acuity (BCVA) score on early treatment of diabetic retinopathy study (ETDRS) chart of ≥ 35 letters (corresponding to ≥ 0.1 Snellen decimal units or ≤ 1.0 Logarithm of the Minimum Angle of Resolution (Chart) [LogMAR]) in each eye at the time of study enrollment.
  • Only participants who satisfy all requirements will be included in the study.

Key Exclusion Criteria:

  • Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
  • Evidence of an active ocular infection in either eye.
  • Anticipated need for ocular surgery during the study period, or any prior ocular surgery for 6 months prior to screening.
  • Intraocular inflammation defined as anterior chamber cell or flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading in either eye.
  • Known or suspected ocular (ocular surface, intraocular, ocular adnexa) in either eye.

Note: Additional protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
417 participants (estimated)

Study arms

  • Experimental
    DFL24498

    Participants will receive DFL24498 opthalmic solution administered topically in both eyes.

    Drug: DFL24498

  • Placebo comparator
    Vehicle

    Participants will receive vehicle opthalmic solution administered topically in both eyes.

    Other: Vehicle

Interventions

  • DrugDFL24498

    One drop of reconstituted DFL24498 will be instilled topically in each eyes 4 times a day (QID) for 12 weeks.

  • OtherVehicle

    One drop of reconstituted Vehicle will be instilled topically in each eyes QID for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in corneal fluorescein staining (CFS) assessed by National Eye Institute (NEI) scale (0 to 15) in the Study Eye

    Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. The CFS is performed at the slit lamp with blue (cobalt) light. The staining is graded using the NEI scale, which scores five corneal zones from 0 to 3 (total corneal score 0-15) with higher scores indicating more extensive staining.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change from baseline in ocular dryness symptom assessed by the global score of the Symptom Assessment in Dry Eye (SANDE) questionnaire

    The SANDE questionnaire includes 2 VAS questions that measure the frequency and severity of DED (each scored 0-100). The global score (0-100) is calculated by multiplying the frequency score by the severity score and obtaining the square root.

    Time frame: Baseline to Week 12]

  2. Change from baseline in tear production assessed by Schirmer I test without anesthesia in the Study Eye

    Before the external ocular examination and post BCVA, the Schirmer I test is performed without anesthesia to measure the wetting of the strip over 5 minutes, and the moistened length is recorded in millimeters (mm).

    Time frame: Baseline to Week 12

  3. Change from baseline; in conjunctival fluorescein staining assessed by NEI scale (0 to 18) in the Study Eye.

    Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Corneal fluorescein staining is performed at the slit lamp with blue (cobalt) light. The staining is graded using the NEI scale, which scores six conjunctival zones from 0 to 3 (total conjunctival score 0-18) with higher scores indicating more extensive staining.

    Time frame: Baseline to Week 12

  4. Number of participants reporting treatment-emergent adverse events

    An adverse event is any untoward medical occurrence in a clinical study participant, associated with the use of study treatment, whether or not it is considered related to the study treatment. Any adverse events occurring or worsening after the first administration of investigational product will be classified as "treatment-emergent" adverse events.

    Time frame: Up to Week 14

07

Study locations

13 of 24 sites recruiting
  • Arizona Eye Center
    Chandler, Arizona 85224, United States
    Recruiting
  • Canyon City Eyecare
    Azusa, California 91702, United States
    Recruiting
  • Global Research Management, Inc.
    Glendale, California 91204, United States
    Recruiting
  • United Medical Research Institute
    Inglewood, California 90301, United States
    Recruiting
  • LoBue Laser and Eye Medical Center
    Murrieta, California 82562, United States
    Not yet recruiting
  • Eye Research Foundation
    Newport Beach, California 92663, United States
    Recruiting
  • NVision Clinical Research, LLC
    Torrance, California 90505, United States
    Recruiting
  • Shettle Eye Research, Inc.
    Largo, Florida 33773, United States
    Not yet recruiting
  • University of South Florida - Marshall Student Center
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Clayton Eye Clinical Research
    Morrow, Georgia 30260, United States
    Recruiting
  • Price Vision Group / Cornea Research Foundation of America
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Minnesota Eye Consultants
    Minnetonka, Minnesota 55305, United States
    Not yet recruiting
  • Tekwani Vision Center
    St Louis, Missouri 63128, United States
    Not yet recruiting
  • Comprehensive Eye Care, Ltd.
    Washington, Missouri 63090, United States
    Not yet recruiting
  • Asheville Eye Associates - Regional Medical Park
    Asheville, North Carolina 28803, United States
    Not yet recruiting
  • Oculus Research, Inc.
    Garner, North Carolina 27529, United States
    Recruiting
  • Core, Inc.
    Shelby, North Carolina 28150, United States
    Not yet recruiting
  • Cincinnati Eye Institute
    Mason, Ohio 45040, United States
    Not yet recruiting
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
    Recruiting
  • Total Eye Care, PA - Memphis
    Memphis, Tennessee 38119, United States
    Recruiting
  • Houston Eye Associates
    Houston, Texas 77025, United States
    Not yet recruiting
  • Lake Travis Eye and Laser Center
    Lakeway, Texas 78738, United States
    Recruiting
  • Alpine Research Organization, Inc.
    Clinton, Utah 84015, United States
    Not yet recruiting
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 7 months is close to that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jan 2027 → Dec 2026 and completion Feb 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartActual
May 12, 2026
Primary completionEst.
Dec 27, 2026was Jan 2027
CompletionEst.
Jan 12, 2027was Feb 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 24, 2027→Dec 27, 2026
Oct 22, 2026
Study completion
Feb 7, 2027→Jan 12, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jan 24, 2027→Dec 27, 2026
    Study completion Feb 7, 2027→Jan 12, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07503886
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
May 12, 2026
Primary completion
Dec 27, 2026 (estimated)
Completion
Jan 12, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
Contact
+39 02 583 831

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion